4,375 Products, Four Days: What China’s Non-VBP Price Governance Means for the IOL Market
The formal compliance window was 30 days. Liaoning delivered four. What cross-provincial price governance means for non-selected IOL products.
China’s VBP procurement framework locks in prices for selected intraocular lenses. For non-selected IOL products and device categories outside the framework, a cross-provincial price linkage system has been tightening since early 2026. In March, it executed its first full sweep: 4,375 products, including IOL, 62 companies, and a four-day decision window. In April, four more provinces moved.
I. What Cross-Provincial Price Linkage Does to Non-Selected IOL Products
For IOL products inside the VBP framework, Zeiss trifocal toric at RMB 18,388, Alcon multifocal toric at RMB 12,996, J&J EDOF toric at RMB 9,090, the price is locked by the procurement agreement for the contract period. For IOL products outside it, non-selected products from companies that did not win or did not participate, the question is what mechanism sets the price floor.
The answer is a national minimum listing price enforced through cross-provincial linkage. Any product listed in one province at a price lower than its current listing elsewhere creates a new national reference. The enterprise must report the new price to all other provinces within a defined window, 30 natural days in most jurisdictions, 20 working days in Jiangsu and Ningxia, and adjust its listings accordingly. The national medical insurance information platform enables real-time cross-province price comparison.
The commercial implication: regional pricing architecture, maintaining higher list prices in premium markets whilst accepting lower prices in volume markets, is structurally incompatible with this system. A price concession made in one province is, within the reporting window, a price concession in every province.
For the IOL category specifically, when Liaoning executed a price governance sweep in March 2026 that explicitly named the intraocular lens category, every price confirmed or declined in that exercise became a data point visible to every other provincial platform. The IOL market now operates under a dual pricing architecture: selected products at locked VBP prices, and non-selected products under cross-provincial linkage pressure. The space between these two regimes is narrowing.
II. The March Execution: What Four Days Looked Like for 62 Companies
In March 2026, Liaoning’s provincial public resources exchange centre issued a price governance notice under Liaoning MHSB Notice on Reforming Centralised Sunshine Listing and Procurement (辽医保规 [2024] 1号), 20 August 2024, targeting non-selected products and products above the VBP price ceiling. The exercise covered four categories: joint replacement, orthopaedic spine, intraocular lenses, and sports medicine. Total scope: 4,375 products across 62 domestic and international enterprises, including major multinational manufacturers’ names.
The notice characterised the exercise as the execution of the national healthcare insurance authority’s price governance priorities, a provincial implementation of a national directive, not a local initiative.
The operational timeline was compressed. Liaoning issued the governance notice on 20 March. Enterprises were required to log into the procurement system and confirm or decline by 24 March, four calendar days. Results were published on 25–27 March. New prices took effect on 31 March.
OphthalLogix assessment: The four-day decision window is the operationally significant data point, not the 4,375 product figure. Four calendar days do not allow a complex pricing decision involving multiple provinces, global pricing implications, and management approval chains. Legal and compliance teams can assess regulatory risk in that window; pricing teams cannot model multi-province implications; management cannot obtain global approvals. The practical outcome: most enterprises accepted the adjusted price, because declining and being delisted carries a greater long-term risk than accepting the reduction. The concession was made not because it had been strategically evaluated but because the window for strategic evaluation had closed.
For IOL companies, this creates a compound problem. Non-selected IOL products already face passive exclusion from public hospital procurement; HIS systems at most hospitals are configured to display only selected or viewed-as-selected products at the clinical ordering point. Now, non-selected products that do maintain listing access face cross-provincial price compression with effectively no decision window. Procurement exclusion plus price governance is not additive. It is multiplicative.
III. Tianjin’s Draft: Price Transparency at the Management Level
Tianjin’s Municipal Healthcare Security Bureau published a consultation draft on 22 April 2026: Tianjin’s consultation draft on medical device listing procurement (《关于深入推进医用耗材挂网采购有关工作的通知（征求意见稿）》), with public comment accepted until 6 May 2026 at 18:00. The document is confirmed on ylbz.tj.gov.cn. This is a consultation draft; its rules carry no legal force until a final version is published with an effective date.
The draft’s principal mechanism is the “three-colour nine-segment line” (三色九段线): a visualisation tool built into Tianjin’s municipal procurement platform since at least 2015, now being codified in regulation. The system displays each device’s current listing price against the distribution of comparable product prices across the city’s purchasing institutions, segmented into low, medium, and high zones. Products in the high-price segment are flagged at the point of procurement review.
Key rules in the draft for non-VBP products: listing price must not exceed the lowest provincial listing price nationally; products without listings elsewhere must provide cost calculations; products with no platform transactions for one continuous year have their listings automatically revoked. VBP-selected products are listed at the VBP-selected price and are not subject to the transparency mechanism’s pricing pressure.
OphthalLogix assessment: Completing VBP procurement volume targets is the binding constraint on hospital procurement committees; it is tied directly to medical insurance fund surplus retention, institutional performance assessments, and management accountability. The three-colour mechanism operates within, not above, that constraint. Its real function is not to override the procurement priority but to serve as a negotiation and audit instrument for everything outside the VBP volume obligation: non-selected products, above-quota purchasing, and categories not yet subject to national procurement. Some hospitals have already incorporated the platform’s price-zone data into their own procurement rules, using the displayed lowest price as the default reference in tender documents. The mechanism has moved from a guidance tool to an institutionalised constraint at the facility level. For non-selected IOL products attempting to maintain hospital access through the viewed-as-selected pathway, this means the price comparison with selected alternatives is now visible, documented, and auditable at the formulary decision point, not as a suggestion, but as a procurement rule the committee is accountable for.
IV. Four Provinces in April: The Pattern
Guizhou (黔医保发 [2026] 7号, 10 April 2026, effective 1 June): national minimum price mandatory, 30-day dynamic adjustment requirement, price verification from at least three provincial platforms required.
Sichuan (川药招 [2026] 1号, 4 January; price updates under 川药招 [2026] 63号, effective 1 April): national minimum listing price as mandatory reference, verified across all provinces, 30-day update window.
Liaoning April actions (16th batch routine price adjustments, effective 29 April, one-week transition): this batch covers general consumables under the 辽医保规 [2024] 1号 framework. It is separate from the March IOL-specific governance sweep but operates under the same price linkage architecture.
Tianjin (consultation draft, 22 April, comment deadline 6 May): architecture-level document codifying the three-colour transparency mechanism and full national price linkage rules for all listed products.
The provinces are not innovating independently. They are implementing a national framework on provincial timelines. The concentrated activity in April 2026 across Guizhou, Sichuan, Liaoning, and Tianjin, following Liaoning’s March IOL execution, indicates that cross-provincial price governance has moved from policy design to operational deployment.
V. Policy-Execution Gap: 30 Days on Paper, Four in Practice
The formal policy text across multiple provinces specifies a 30-day window for enterprises to report and adjust prices following a new national low. Hebei and Hainan cite 30 natural days. Jiangsu and Ningxia compress to 20 working days. Zhejiang allows approximately 14 days.
The policy-execution gap is the distance between these formal windows and the reality of a point-name governance exercise. When a provincial bureau identifies a cohort of non-compliant products and issues a batch correction notice, the administrative timeline is not bound by the formal reporting window. Liaoning’s four-day window in March was not a deviation from policy; it was an exercise of administrative discretion within the framework of the 辽医保规 [2024] 1号.
For pricing teams, this gap has a direct operational implication. A compliance function built around the formal 30-day window will fail when the actual execution uses a point-in-time model. The relevant planning assumption is not “we have 30 days to respond” but “we may have four days, and those four days may begin without prior warning.”
VI. Key Implications
For market access teams managing non-selected IOL portfolios in China: the architecture described here was already executed in March across the IOL category. Immediate action: audit whether your China pricing architecture assumes any meaningful price differentiation across provinces for non-selected IOL products. If it does, that architecture is not compatible with the current direction. Cross-provincial price linkage compliance needs to be built into your listing decision process, not handled reactively after a governance notice arrives.
For companies with selected IOL status (Zeiss/Shanghai Pharma, Alcon, J&J/CR Guangdong, AiBo): VBP selected prices are protected during the current contract period (ending mid-2026). The three-colour mechanism and cross-provincial linkage do not directly compress selected prices within the agreement period. The indirect risk is in the next procurement cycle: the price data generated by the transparency mechanism now forms part of the baseline for future negotiations.
For companies without selected status relying on the viewed-as-selected pathway: the pathway offers formulary access but not quota credit. The three-colour mechanism makes the price comparison between your product and selected alternatives visible at the management level. The combination of no quota credit, management-level price visibility, and cross-provincial linkage pressure is a structurally difficult position. The question is not whether to act but whether action before the third procurement year (mid-2026) is still possible.
For investors: the March Liaoning exercise is the clearest available signal of how non-VBP price governance will operate across high-value device categories. 4,375 products, 62 enterprises, four-day window, executed as a national directive. Valuation models that assign meaningful probability to regional price differentiation for non-selected device products in China should be revisited.
This content is for informational purposes only and does not constitute legal, regulatory, investment, or medical advice. China’s healthcare policy environment moves quickly; the status of any regulatory development should be verified independently before informing a commercial or compliance decision. OphthalLogix Intelligence accepts no liability for decisions made in reliance on this content.
— The OphthalLogix Intelligence Team · www.ophthallogix.com · intelligence@ophthallogix.com
